Third Harmonic Bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Natalie C. Holles
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Technology Square Cambridge MA United States of America 02139
- IPO Date
- Sep 14, 2022
- CIK
- 0001923840
- Website
- thirdharmonicbio.com
- Similar Companies
- Business
- Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development of highly selective, oral small-molecule KIT inhibitors targeting mast cells, which are key drivers of inflammation. The company's lead product candidate, THB335, is designed to provide symptomatic relief for a range of dermal, respiratory, and gastrointestinal inflammatory diseases including chronic spontaneous urticaria and severe asthma. The oral formulation of THB335 offers a convenient administration route for patients requiring chronic treatment. Third Harmonic Bio focuses on advancing novel immunotherapies aimed at improving patient outcomes in allergic and inflammatory diseases, leveraging the inhibition of KIT, a cell surface receptor critical to mast cell survival and function. The company was founded and is headquartered in Cambridge, Massachusetts, operating within the biotechnology sector and targeting markets including dermatology, pulmonology, and gastroenterology. Third Harmonic Bio’s clinical development approach emphasizes rigorous scientific validation and regulatory engagement, intending to submit regulatory filings to the U.S. Food and Drug Administration (FDA) for Phase 2 clinical trials of THB335. In recent major corporate developments within 2024 and 2025, Third Harmonic Bio has advanced the clinical profile of THB335, completing multiple ascending dose cohorts in Phase 1 trials demonstrating promising pharmacokinetics, pharmacodynamics, and safety profiles. However, in 2025, the company announced a strategic shift to liquidate operations and initiated the sale of THB335 and related intellectual property, following stockholder approval of a plan of liquidation and dissolution. This decision came after halving its workforce and ceasing further R&D programs beyond Phase 1 readiness activities. The company has planned to return cash to shareholders and pursue asset sales as the best path forward, marking a significant operational change from active clinical development toward dissolution. These strategic moves reflect Third Harmonic Bio’s response to the biopharmaceutical market environment and clinical pipeline status, ending its efforts to advance THB335 independently while seeking to maximize shareholder value through asset sales. The company has maintained its focus on its core asset, THB335, during this process, with all clinical, toxicology, and manufacturing activities required for Phase 2 readiness now complete. Overall, Third Harmonic Bio, Inc. combines a focused biopharmaceutical development platform in inflammation and allergy with a recent operational realignment towards asset liquidation, headquartered in Cambridge, Massachusetts, with a legacy of pioneering a novel oral KIT inhibitor therapy for inflammatory diseases.
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference